Our lead candidate, V4C 232, is a fully synthetic, optimized molecule inspired by a naturally occurring peptide . Its unique aquaretic and anti cystic properties open the way to breakthrough therapies for life threatening conditions.
Our Lead Candidate: V4C 232
A first in class therapy for refractory ascites
V4C 232 is being developed as a novel treatment for refractory ascites in liver cirrhosis, a critical condition with no approved drug therapy. Approximately 10% of patients with ascites progress to refractory forms, dramatically worsening prognosis and quality of life.
Preclinical studies demonstrate that V4C 232 provides potent, safe, and selective aquaretic activity, offering a promising therapeutic solution for patients who no longer respond to diuretics.
A new therapeutic option for polycystic kidney diseases (ADPKD & ARPKD)
V4C 232 also shows strong efficacy in models of autosomal dominant polycystic kidney disease, rare genetic disorder that progressively leads to renal failure. Therapeutic options remain extremely limited, especially for children. Our data highlight the ability of V4C 232 to reduce cystogenesis and improve renal parameters in multiple experimental models.
Clinical Development Roadmap
V4Cure is advancing V4C 232 through pharmacological and regulatory development to prepare its entry into clinical phases 1 and 2 for proof of concept in refractory ascites. Meanwhile, V4Cure is also developing another V4C-232-based product as a new therapy for polycystic kidney diseases (ADPKD and ARPKD).
PhD in human biology
25 years in pharma R&D, 20 years in biotech management and creation
PharmD, PhD in immunochemistry
20 years in pharma industry
10 years on the equity market
PhD in Biochemistry, Molecular & Cellular Biology,
12 years of academic research, 8 years in biotech.
Ph.D in Neurosciences and Cancer Biology.
+15 years in biotech BD,
Former CEO of EMGLEV Therapeutics
PhD in biochemical pharmacology
20 years in research at CEA
5 patents and 76 publications
MBA, expertise in international finance for large and small healthcare companies
30-years in Pharma & Biotech industry
9-years on Pharma & Care Boards
Centrale Engineer, Former Abbott executive, 20-years in M&A, Life Science investments
MBA, 30-years in Pharma & Biotech industry
Jellagen CEO, Biotechs Board member
25-years in Health Care and Lite Sciences strategic consulting. Managing Partner at AEC Partners.
V4Cure is a spin-off of CEA.
V4Cure received the national ILAB grant
for innovation with the Honor Award in 2022.
V4Cure is a member of Paris Biotech Santé Biotech incubator.
